Welcome! We look forward to meeting you and discuss how iPSC technology can support your projects.
Ncardia is a pioneering company focused on expediting therapy delivery to patients by incorporating human biology in early drug discovery. With expertise in automated screenings, we aid therapeutic developers in making informed decisions sooner, conserving time and resources. Our custom disease models accurately emulate human biology in vitro, enhancing predictability during initial drug discovery. Proficiency in large-scale cell type manufacturing ensures scalability with minimal batch variation. Offering a range of assays for specific phenotypes and clinically relevant readouts, our automated platforms minimize variability, bolstering confidence in crucial decision-making stages. By integrating human iPSC technologies, we accelerate progress and enable early critical decisions in drug development. Ncardia is committed to equipping clients with tools and expertise to bridge the translatability gap, transforming drug discovery and hastening life-changing therapies for patients.